(Q33349587)

26 July 2017

title

Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial (English)

1 reference

26 July 2017

main subject

phase III clinical trial

0 references

1 reference

1 reference

1 reference

Milada Zemanová

3

0 references

Miloš Pešek

object named as

Milos Pesek

6

0 references

Luboš Petruželka

object named as

Lubos Petruzelka

2

0 references

author name string

Petr Zatloukal

1

1 reference

26 July 2017

Vítezslav Kolek

4

1 reference

26 July 2017

Jana Skricková

5

1 reference

26 July 2017

Hana Fojtů

7

1 reference

26 July 2017

Ivona Grygárková

8

1 reference

26 July 2017

Dimka Sixtová

9

1 reference

26 July 2017

Jaromír Roubec

10

1 reference

26 July 2017

Eva Horenková

11

1 reference

26 July 2017

Libor Havel

12

1 reference

26 July 2017

Petr Průsa

13

1 reference

26 July 2017

Leona Nováková

14

1 reference

26 July 2017

Tomás Skácel

15

1 reference

26 July 2017

Milan Kůta

16

1 reference

26 July 2017

publication date

1 September 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

41

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

321-331

1 reference

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Non-small cell lung cancer: an overview of current management

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Gemcitabine: a pharmacologic and clinical overview

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Onc

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

A prospective study of gemcitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three- versus a four-week schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Gemzar platinum combinations: phase III trials in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900233-2

7 January 2021

10.1016/S0169-5002(03)00233-2

Identifiers

DOI

1 reference

26 July 2017

1 reference